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SUMMARY
We discovered a high-level amplicon involving the chr19q13.41 microRNA (miRNA) cluster (C19MC) in 11/45
(25%) primary CNS-PNET, which results in striking overexpression of miR-517c and 520g. Constitutive
expression of miR-517c or 520g promotes in vitro and in vivo oncogenicity, modulates cell survival, and
robustly enhances growth of untransformed human neural stem cells (hNSCs) in part by upregulating WNT
pathway signaling and restricting differentiation of hNSCs. Remarkably, the C19MC amplicon, which is
very rare in other brain tumors (1/263), identifies an aggressive subgroup of CNS-PNET with distinct gene-
expression profiles, characteristic histology, and dismal survival. Our data implicate miR-517c and 520g
as oncogenes and promising biological markers for CNS-PNET and provide important insights into onco-
genic properties of the C19MC locus.INTRODUCTION
Brain tumors are the leading cause of childhood cancer-related
morbidity and mortality. Primitive neuroectodermal tumors
(PNET), which are the most frequent malignant pediatric brainCtumors, include medulloblastoma, a cerebellar PNET, and
CNS-PNET (also called supratentorial PNET or sPNET)—an
aggressive cerebral tumor (McLendon et al., 2007). Comprehen-
sive genetic studies of a substantial number of CNS-PNET have
not yet been undertaken due to their relative rarity. Lack ofSIGNIFICANCE
Lack of insight into diseasemechanisms impedes development of effective therapies formany human neoplasms, including
childhood brain tumors such as CNS-PNET. Through global genomic studies, we discovered a frequent high-level amplicon
of a polycistronicmiRNA locus (C19MC), which defines aggressive CNS-PNET, and provide functional evidence thatC19MC
miRNAs act as oncogenes. Interestingly, althoughC19MC amplification remains to be reported in other cancers, expression
of C19MCmiRNAs has also been linked to unfavorable breast cancer phenotypes. Together with our discovery of recurrent
C19MC gene amplification in a highly malignant brain tumor, these data highlight C19MC as an attractive candidate
biomarker and therapeutic target for aggressive human cancers and support an emerging theme that miRNAs are important
determinants of tumor biology.ancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Inc. 533
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Oncogenic miRNA Cluster in Embryonal Brain Tumorinsight into the molecular pathogenesis of CNS-PNET is a major
obstacle toward development of disease-specific models and
treatments for these frequently fatal tumors.
CNS-PNET, which represent 3%–7% of all pediatric brain
tumors, are a heterogeneous group characterized by primitive
neuroepithelial cells with variable neuronal, glial, or ependymal
differentiation. Unlike rhabdoid tumors, which are defined by
INI1 gene alterations (Allen et al., 2006), CNS-PNET may pose
significant diagnostic challenges due to lack of characteristic
genetic or immunohistochemical markers (McLendon et al.,
2007). In addition to CNS-PNET, several other PNET histologic
variants may arise in the cerebral hemispheres: these include
ependymoblastoma and medulloepithelioma, which have char-
acteristic histologic features such as ependymal rosettes and
primitive neural tube formation, and ENATR, a newly described
entity with ependymoblastic differentiation (Gessi et al., 2009;
McLendon et al., 2007). Whether CNS-PNET and PNET variants
represent distinct molecular tumor subtypes remains debated
(Burger, 2006; Judkins and Ellison, 2008).
CNS-PNET and medulloblastoma share very similar histology
and are largely distinguished by tumor location. However, CNS-
PNET are more aggressive tumors with significantly inferior
outcomes (Fangusaro et al., 2008; Timmermann et al., 2006)
than medulloblastoma (Packer et al., 2006). Cumulative data
suggest CNS-PNETs and medulloblastoma have distinct genetic
features and histogenesis. Notably, CNS-PNET lack expression
of cerebellar granule cell-specific transcription factors (Pomeroy
et al., 2002) and isochromosome 17q (i17q), which characterize
medulloblastoma (Inda et al., 2005; McCabe et al., 2006; Pfister
et al., 2007) and rarely arise in murine medulloblastoma models
(Zindy et al., 2003).
Limited CGH studies indicate CNS-PNETs are genetically
heterogeneous with frequent but diverse copy number aberra-
tions (CNAs). Genes targeted by CNAs in CNS-PNET remain
largely unknown; to date, amplification of MYCN, PDGFB and
PDGFRA, and CDKN2A/2B deletions have been reported (Inda
et al., 2005; McCabe et al., 2006; Pfister et al., 2007). However,
the significance of these and other reported genetic alterations
to the biology and clinical phenotypes of CNS-PNET is not
known.
MicroRNAs (miRNAs) are short 22 nucleotide noncoding
RNA that function as important regulators of gene expression
in various cell types. They are implicated in diverse biological
processes, including self-renewal and pluripotentcy (Bar
et al., 2008), and as etiologic genes in various human malignan-
cies (Esquela-Kerscher and Slack, 2006). Patterns of miRNA
expression have been shown to distinguish tumor types and
to predict tumor biology (Lu et al., 2005). Direct genetic alter-
ations of a few miRNAs have also been reported in human
cancers: these include MiR15/16a in CLL (Calin et al., 2002),
MIR-17-92 in B cell lymphoma (He et al., 2005), and LET-7 in
lung cancer (Johnson et al., 2005). Although miRNAs have
been implicated in malignant gliomas (Papagiannakopoulos
et al., 2008), their role in malignant pediatric brain tumors
remains largely unexplored.
In this study, we sought to comprehensively define genetic
alterations in CNS-PNET by performing high-resolution DNA
copy number and gene expression analysis on a substantial
number of primary tumors.534 Cancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier IncRESULTS
Identification of a Frequent High-Level Amplicon
at chr19q13.41 in CNS-PNET
We performed high-resolution copy number and gene-expres-
sion analyses on 39 and 33 primary tumors, respectively (Table
S1 available online). Global DNA copy number determined using
the 500K Affymetrix SNP arrays and dChip analysis (Lin et al.,
2004) revealed frequent and multiple CNAs (10–28/tumor) in
most tumors (Figure S1; Tables S2 and S3) and collectively
confirm prior observations (Inda et al., 2005; McCabe et al.,
2006; Pfister et al., 2007) that CNS-PNET are a genetically
heterogeneous but distinct group of embryonal brain tumors.
Despite substantial genomic heterogeneity, we observed
recurrent chr2 gains and focal chr19q13.41 amplification in a
significant proportion (8/39) of CNS-PNET. Two tumors had
nonoverlapping chr2p24.3 and chr2q33.3 amplicons encom-
passing MYCN and putative oncogenes, CREB1 and FZD5
(Figure 1A); however, gene-expression profiles did not correlate
MYCN, CREB1, or FZD5 expression with chr2 gains in tumors
(data not shown). In contrast, the chr19q13.41 amplicon in all
eight tumors mapped to a common 1 Mb interval between
the DPRX and LILRP2 loci (Figure 1B). Notably, the
chr19q13.41 amplicon was absent in matched lymphocyte
DNA of an additional tumor PNET 54 (Figure 1C), indicating it
was tumor specific and not a normal DNA copy number variant
(Iafrate et al., 2004). We used FISH analyses to validate the gen-
otyping data (Figure 1D), and to test for the chr19q13.41 ampli-
con in five additional tumors that were not included in genotyping
analysis. Collectively, the amplicon was detected in 25%
(11/45)of tumorsanalyzed,a remarkably high frequency indicating
an important CNS-PNET oncogene(s) maps to chr19q13.41.
MicroRNAs of the C19MC Locus Are the Targets
of the chr19q13.41 Amplicon
Genotyping and qPCR analysis indicated the minimal
chr19q13.41 amplicon in CNS-PNET spanned 34 protein-coding
loci and 2 miRNA clusters (Figures 2A and 2B). We examined
transcriptional profiles of 33 CNS-PNET by t tests to determine
if any coding loci exhibited copy number-driven changes in
expression (Figure 2C); qRT-PCR validation of select genes is
shown in Figure S2A. Only one gene exhibited a modest 2-fold
increase in expression (CNOT-3; p = 0.02), indicating miRNA
clusters as likely targets of the chr19q13.41 amplicon. The
chr19q13.41 amplicon spans a large, poorly characterized,
primate-specific miRNA cluster, C19MC and the MIR-371-373
locus, which map 100 kb apart. Although miR371-373 has
been implicated in germ cell tumors (Voorhoeve et al., 2006), little
is known regarding the oncogenic potential of the C19MC locus
that encodes 54 predicted miRNA (Bentwich et al., 2005).
To identify potential oncogenic miRNAs, we used a miRNA
array to assay expression of the C19MC and MIR371-373 clus-
ters (Table S4) in chr19q13.41-amplified tumors. These analyses
revealed robust expression of severalC19MCmiRNAs in tumors
relative to fetal brain, but only modest expression of miR371-373
(Figure 2D). With exception of miR-512-3p and 520c-3p, miRNA
levels were confirmed by gene-specific qRT-PCR (Figures S2B–
S2D) and significantly correlated (p < 0.0001) with chr19q13.41
amplification (Figure 2E). We observed highest tumor-specific.
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Oncogenic miRNA Cluster in Embryonal Brain TumorFigure 1. Frequent chr2 Gains and chr19q13.41 Amplication in CNS-PNET
Global DNA copy number profiles of 39 CNS-PNET were generated using the Affymetrix 500K SNP arrays (Figure S1). (A) and (B) show inferred DNA
copy numbers as determined using dChip for SNPs on chromosomes 2 and 19 with DNA gains and losses indicated by shades of red.
(A) Expanded copy number profiles of chr2 showing frequent whole chr2 gains in tumors; amplicons encompassing MYCN and candidate oncogenes,
CREB1 and FZD5, in two individual tumors are shown on the right.
(B) Expanded view illustrating overlapping boundaries of the chr19q13.41 amplicon, which is flanked by the DPRX and LILRP2 loci in 8/39 tumors (red labels).
Copy number plot of an individual tumor is shown on the right.
(C) Inferred copy number plots generated using dChip pair-matched analysis reveals the chr19q13.41 amplicon in tumor, but not matched normal lymphocyte
(PBL) DNA of PNET54.
(D) Fluorescence in situ hybridization confirms high-level chr19q13.41 DNA copy number gains and amplification, respectively, in tumors PNET 3 and 5 and 6 as
indicated by genotyping analysis.Cancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Inc. 535
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Oncogenic miRNA Cluster in Embryonal Brain TumorFigure 2. MicroRNAs Are the Oncogenic Target of the chr19q13.41 Amplicon
(A) Genomic organization of the chr19q13.41 amplicon, which maps between the DPRX and LILRP2 loci, is schematized. Relative map positions of the chr19
microRNA cluster (C19MC) (red), theMIR371-373 cluster (blue), and select coding genes within the amplicon boundaries are shown. Asterisks (*) mark candidate
oncogenicMIR-520g and 517c;MIR-512-1 andMIR-516-1a mark the limits of the locus. BAC clone RP11-381E3, used for FISH analysis, is indicated in green. All
map positions are based on the hg18 build from the UCSC Genome Database (http://genome.ucsc.edu/). Lower panel shows a DNA copy number plot of SNPs,
indicating overlapping boundaries of the chr19q13.41 amplicon in nine tumors.
(B) Confirmation of chr19q13.41 amplicon boundaries in nine tumors by qPCR copy number analysis of select loci. Result is representative of two independent
experiments.
(C) Heat map showing expression levels of 34 coding genes on chr19q13.41 as determined from BeadChiP expression analysis of 33 tumors; q values indicate
significance of gene expression changes relative to chr19q13.41 amplification, asterisk (*) indicates the CNOT3 locus which showed a modest 2-fold gene
expression change in chr19q13.41 amplified tumors, and z indicates select genes validated by qRT-PCR (Figure S2A).
(D) TaqMan microRNA array analysis of seven tumors with chr19q13.41 amplification indicate high expression of several C19MC miRNAs (miR-512-3p, 517a,
520g, 517c, 519a), but not miR371-373, in tumors relative to fetal brain (Figures S2B–S2D).
(E) Box and whisker summary plot showing expression levels of ten select C19MC miRNA relative to chr19q13.41 amplification in tumors; qRT-PCR analysis of
eight amplified and 15 nonamplified tumors is shown. Paired boxes represent the 25th–75th percentile expression values for each miRNA in tumors without ()
and with (+) theC19MC amplicon. Horizontal bars indicate median, while vertical lines indicate maximum and minimum miRNA expression values for each tumor
group; asterisks (*) denote significant correlation of miRNA expression levels withC19MC amplification; and error bars represent SEM of nR 2 with three replicas.536 Cancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Inc.
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Oncogenic miRNA Cluster in Embryonal Brain Tumorexpression (up to 403 greater than other miRNAs) of miR-520g
and miR-517c in chr19q13.41-amplified tumors (Figure 2F)
and, therefore, focused on miR-520g and 517c to test for onco-
genic potential of the C19MC locus.
miR-520g and 517c Have Oncogenic Effects
In Vitro and In Vivo
To test if miR-520g and 517c have oncogenic properties, we
characterized the effects of stable miRNA expression
(Figure 3A) in hemispheric PNET (PFSK) and medulloblastoma
(Daoy) cell lines, which have low endogenous miR-520g and
517c expression (Figure S3), as well as murine NIH 3T3 cells
using growth, soft agar transformation and nude mouse xeno-
graft assays. Although, the C19MC locus is primate specific,
we hypothesized that genes with important oncogenic functions
will target conserved, critical downstream pathways across
species and cell types. Indeed, miR-520g or 517c expression
enhanced cell growth and/or transformation in all three cell types
(Figures 3B–3D). Interestingly, we observed cell-type and
miRNA-dependent phenotypic changes that were not associ-
ated with relative miRNA levels. While miR-517c expression
enhanced growth of all three lines (p < 0.001) and promoted
soft agar growth and xenograft Daoy, NIH 3T3-miR-517c cells
exhibited limited in vitro transformation (Figure 3C) but formed
robust xenografts (Figure 3D). Similarly, miR-520g expression
had limited effects on cell growth (Figure 3B) but promoted
soft agar growth and xenograft formation in Daoy and NIH 3T3
cells (Figures 3C and 3D). These observations collectively
support oncogenic functions for miR-520g and 517c and
suggest that, like other oncogenic miRNAs (Bonci et al., 2008),
miR-520g and 517c may effect cell transformation via multiple
mechanisms.
miR-520g and 517c Expression Promotes Cell Survival
and Inhibits Neural Stem Cell Differentiation
To investigate how miR-520g or 517c might drive oncogenesis,
we examined tumor transcriptional profiles to identify gene-
expression changes most significantly correlated with C19MC
amplification using t test statistics (Figure 4A). A resulting set
of 381 and 501 genes, respectively, with up- and downregulation
(Table S5) in C19MC-amplified tumors were further investigated
using the gene function annotation tool GOSTAT (Beissbarth and
Speed, 2004) (Table S6). Interestingly, apoptosis regulators were
significantly downregulated in C19MC-amplified tumors (22 of
501 genes, p = 5.57E8); 11/22 genes, including API5, BAD,
and TRADD, had proapoptotic functions. Consistent with these
observations, miR-520g or 517c expressing PFSK, Daoy, and
NIH 3T3 cells exhibited increased cell viability and decreased
apoptosis in serum-deprived media (Figures 4B and 4C). Collec-
tively, these data indicate that miR-520g and 517c promote
oncogenesis in part by modulating cell survival pathways.
Interestingly, GOSTAT analyses also revealed enrichment of
developmental signaling genes in C19MC-amplified tumors
(83 of 381 genes, p = 4.79E26; Table S6). In particular, self-
renewal and survival genes, including SOX11, NR2F1, NKX2-2,CFGF13, FGFr3, SALL4, and WNT pathway ligands (WNT5A
and -7A) and receptors (FZD2, -3, -7, and -10) were overrepre-
sented. We investigated if ectopic miR-520 g or 517c expression
could alter the phenotype of primary human neural stem cell line
(hNSC), which normally continually replicate in growth-pro-
moting/proliferative media containing high FGF and EGF, but
undergo growth arrest in factor-deprived/differentiation condi-
tions such as 10% serum media (Sun et al., 2008). Stable
hNSC-miR-520g and 517c cells did not exhibit significant
changes in growth under proliferative conditions (Figure S4);
however, miR-520g and to a lesser extent, miR-517c expression,
strikingly enhanced hNSC growth in differentiation media
(Figures 5A and 5B; Figure S4), indicating that miR-520g or
517c may alter the differentiation potential of hNSCs.
We used immunocytochemical and qRT-PCR analyses to
compare expression of Tubulin b-III and GFAP, which respec-
tively mark neuronal and astrocytic differentiation, in hNSC-
miR-520g and 517c cells grown in proliferative and differentia-
tion conditions. GFAP expression was not significantly altered
in hNSCs-miR-520g and 517c cells as compared to controls
(data not shown). Notably, although hNSCs-miR-520g or 517c
cells did not exhibit significant changes in Tubulin b-III expres-
sion under proliferative conditions, Tubulin b-III expression in
hNSC-miR-520g cells grown in differentiation media was
strikingly diminished as compared to controls (15% versus
65% Tubulin b-III positivity; Figures 5C and 5D). Interestingly,
qRT-PCR analysis revealed expression of NKX2-2 and OLIG1,
two genes with essential roles in normal neuronal cell-fate
specification and differentiation (Briscoe et al., 2000; Zhou and
Anderson, 2002), was also diminished in miR-520g, as well as
517c-expressing hNSCs (Figure 5D). We also observed that
robust effects of miR-520g on hNSC differentiation was accom-
panied by striking changes in expression of neural stem/progen-
itor cell markers in hNSCs grown under differentiation condi-
tions. Specifically, qRT-PCR analysis revealed upregulation of
early neural stem/progenitor cell markers CD44, CD133, and
POU3F2 in stable hNSC-miR-520g, as well as 517c cells grown
in proliferative media, but only hNSC-miR-520g cells maintained
or exhibited robust expression (3- to 7-fold greater than
controls) of neural stem/progenitor cell markers in differentiation
media (Figure 5E). These data suggest that miR-520g, and to
a more limited extent, miR-517c, promotes hNSC growth by
restricting differentiation and enhancing neural stem/progenitor
cell phenotypes.
Interestingly, expression of severalC19MCmiRNAs, including
miR-520 g, has also been correlated with human ES cell (hESC)
differentiation (Bar et al., 2008). Together with our observations,
these data highlight an important role for miR-520g and possibly
other oncogenic C19MC miRNAs in maintenance of primitive/
progenitor cell phenotypes.
miR-520g Expression Correlates with Altered
WNT Signaling
Substantial data implicate aberrant developmental signaling
in the pathogenesis of embryonal brain tumors, including(F) Gene-specific qRT-PCR confirms high expression of select C19MC miRNAs in chr19q13.41-amplified tumors relative to normal fetal brain (Figure S2);
miR-520g and 517c had highest tumor-specific expression (red arrows) in seven tumors analyzed; error bars represent SD of n R 2 experiments (3 replicas/
experiment); and miRNA levels shown in (DF) were determined relative to RNU6B control.ancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Inc. 537
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Oncogenic miRNA Cluster in Embryonal Brain TumorFigure 3. miR-520g and 517c Have Oncogenic Effects In Vitro and In Vivo
(A) Quantitative RT-PCR confirmation of stable miR-517c or 520g expression in PFSK, Daoy, and NIH 3T3 cell lines; miRNA levels are relative to RNU6B. Results
are shown as means ± SD; nR 2 to 3. Cell line pools were used for experiments shown in (B–D).
(B) Growth curves of miR-520g or 517c-expressing PFSK, Daoy, and NIH 3T3 stable cell lines indicate significant growth advantage in miR-517c (upper panel),
but not miR-520g expressing (lower panel) cells in 10% serum conditions. Data represent three independent experiments with three replicas/data point;
error bars, SD.
(C) MicroRNA 520g and 517c expression significantly enhances colony formation in Daoy, but not PFSK or NIH 3T3 cells; two independent soft agar growth
assays with 3 replicas/data point are summarized, and error bars denote SD.
(D) Control and miR-520g or 517c expressing Daoy and NIH 3T3 stable cell lines were injected into contralateral flanks of nu/nu mice as described in methods.
Histogram represents tumor weights from eight mice determined 6 weeks postinjection; error bars represent SEM. Right panel shows representative mice with
Daoy or NIH 3T3 miR-520g or 517c associated xenografts (red arrow); *control injection sites.CNS-PNET (Fogarty et al., 2005). Indeed, expression analysis
revealed significant enrichment of developmental signaling
genes, particularly those of the WNT pathway in C19MC-ampli-538 Cancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Incfied CNS-PNET (Figure 4A; Table S6), indicating that one or more
C19MC miRNA genes may function in WNT signaling. Notably,
the WNT pathway, which plays a critical role in neural stem.
Cancer Cell
Oncogenic miRNA Cluster in Embryonal Brain TumorFigure 4. C19MC Amplification and Constitutive miR-517c and 520g Expression Is Associated with a Survival Phenotype
(A) Expression profiles demonstrate significant enrichment of self-renewal and survival genes in C19MC-amplified tumors. Heat map shows up (red arrow)- and
down (green arrow)-regulated genes identified using a moderated t test statistic adjusted for multiple testing (FDR < 0.05) and analyzed for functional enrichment
using GOSTAT (Tables S5 and S6). Significance and magnitude of gene expression changes between the two tumor groups are denoted respectively by p-value
and fold change.
(B and C) PFSK, Daoy, and NIH 3T3 cells with stable miR-520g or 517c expression were exposed to 0.1% serum and assayed for cell viability or apoptosis relative
to similarly treated control cells. (B) shows a representative plot of relative cell viability at 72 hr determined by trypan-blue staining; error bars represent SD;
n = 3 with 3 replicas. (C) shows results of TUNEL assays in miR-520g and 517c stable and control lines at 72 hr after serum starvation; three experiments
(two replicates/data point) are summarized; error bars represent SD, percent (%) apoptosis equal ratio of TUNEL to DAPI-positive cells.cell survival and lineage determination (Kalani et al., 2008;
Wexler et al., 2009), has been linked to miR-520g by recent
computational studies (Gaidatzis et al., 2007). We focused on
miR-520g to investigate signaling pathways associated with
the C19MC oncogenic locus, as miR-520g expression corre-
lated with the most robust phenotypic changes in hNSCs.
To uncover signaling pathways associated with miR-520g
cellular phenotypes, we performed gene expression analysis of
hNSC-miR-520g and PFSK-miR-520g and control cell line using
the Illumina BeadChip arrays and used t tests to identify gene
sets most significantly correlated with miR-520g expression.
Not surprisingly, consistent with broad regulatory functions of
miRNAs, we observed substantial gene expression changes in
both hNSCs and PFSK cells with stable miR-520g expression;
1000 to 5000 differentially expressed genes were respectively
identified in PFSK and hNSC cell lines with miR-520g expression
(p < 0.05). Functional analyses of miR-520g targets predicted by
several different algorithms and of the miR-520g-associated
gene sets determined from both cell line gene expression data
consistently revealed most significant enrichment of genes
with functions in neural development (data not shown). We
therefore performed gene enrichment analysis on miR-520g-
associated gene sets to investigate if developmental signaling
pathways, which have been implicated in embryonal brain tumorCdevelopment, including the WNT, SHH, NOTCH, and TGF-b
pathways, were altered by miR-520g expression. We used the
KEGG pathway database to identify and determine the number
of specific pathway genes assayed by the Illumina BeadChip
and applied multiple hypotheses testing to calculate relative
representation of each pathway in the miR-520g-associated
gene sets. Strikingly, consistent with observations in C19MC-
amplified primary tumors (p = 1.3E5), these analyses revealed
most significant enrichment of WNT pathway loci in hNSC-miR-
520g (p = 1.3E8) and a similar more modest trend in PFSK-miR-
520g cells (p < 0.016) (Table S7; Figure 6A).
The WNT pathway encodes a complex network of ligand and
receptor combinations which signal via b-catenin-dependent
(canonical) or independent (noncanonical) pathways in various
cell contexts. While expression of WNT2/3 class ligands typically
increase canonical WNT activity and upregulate downstream
proliferative genes, such as CCND1 and MYCC, the WNT5A
ligand family classically activate noncanonical signaling but
may also regulate the canonical pathway (Miller, 2002). Interest-
ingly, in both hNSCs and PFSK cells, miR-520g expression
correlated with upregulation of WNT5A, as well as SFRP2/3
and DKK1 genes, which encode antagonists of the canonical
WNT pathway (Table S8). We confirmed upregulation of
WNT5A, SFRP2/3, and DKK1 in hNSCs and PFSK-miR-520gancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Inc. 539
Cancer Cell
Oncogenic miRNA Cluster in Embryonal Brain TumorFigure 5. miR-520g and 517c Expression Drives Growth and Inhibits Differentiation of Human Neural Stem Cells
(A) Quantitative RT-PCR confirmation of stable miR-520g or 517c expression in hNSCs. Results are shown as means ± SD; n = 3; cell pools were used for
all experiments.
(B) hNSCs-miR-520g and hNSCs-517c cell lines were exposed to differentiation media (DMEM +10% FBS) and monitored for changes in confluence with a
live-cell imaging system. Photos on day 8 postdifferentiation (bottom panel) show no differences in cell mass; therefore, cell confluence was used to estimate
cell numbers. In contrast to control cells, hNSC with stable miR-520g and 517c expression continued to grow in differentiation media.
(C) FACS analysis of stable hNSC-miR-520g and 517c and control pcDNA cell lines stained for neuronal (Tubulin bIII) and astrocytic (GFAP) lineage markers after
growth in proliferative and differentiation media. GFAP expression was not consistently altered in miR-520g- and 517c-expressing cells (data not shown); Tubulin
bIII expression (red boxes and D) was significantly diminished only in hNSCs-miR-520g cells grown in differentiation media.
(D and E) Quantitative RT-PCR analysis of cell lineage and stem cell markers in stable hNSC-miR-520g, 517c, and control hNSC-pcDNA cells grown under
proliferative and differentiation conditions. Relative mRNA levels are normalized to 36B4 controls; *p < 0.05. Results shown are means ± SD; n = 2 to 3, with
two replicas/experiment.540 Cancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Inc.
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Oncogenic miRNA Cluster in Embryonal Brain TumorFigure 6. miR-520g Expression Correlates with Altered WNT Signaling
(A) Summary of pathway enrichment analysis performed on gene expression profiles of hNSCs (left panel) and PFSK (right panel) with stable miR-520g expres-
sion. Expression profiles of stable cell lines generated using Illumina BeadChips were compared to identify genes most significantly correlated with miR-520g
expression in hNSC or PFSK cells. The miR-520g associated gene sets were then analyzed using the KEGG pathway database to determine significance of
enrichment (–log10 [p value]) for specific developmental signaling pathways (bars) (Table S7). Number of genes in each pathway that meet the p value threshold
(log10 [p < 0.05], dashed line) is indicated.
(B and C) Quantitative RT-PCR analysis confirms WNT pathway dysregulation in miR-520g expressing stable hNSC and PFSK cell lines. In hNSCs (B) and PFSK
(C) cells, miR-520g expression correlated with upregulation of WNT ligand, WNT5A, and WNT inhibitors—SFRP2/3 and DKK1. CCND1 and MYCC expression
was diminished in miR-520g expressing cells but did not correlate with canonical WNT reporter activity (Figure S5). Results shown are means ± SD with n = 2, two
replicas/experiment; mRNA levels are normalized to 36B4; *p < 0.05.
(D) Total lysates from control and stable PFSK-miR-520g cell lines were immunoblotted with phosphospecific antibodies for PKC (pPKC), CAMKII (pCAMKII),
JNK1 and -2 (pJNK1, pJNK2), and antibodies for total JNK1 and -2; actin served as loading control. Arrows indicate higher levels of pJNK2, but not pJNK1,
observed consistently in PFSK-miR-520g cells relative to controls without changes in total JNK1/2 levels; a representative of four independent experiments is
shown.cells by qRT-PCR analysis (Figures 6B and 6C). Of note,
although expression of CCND1 and MYCC was diminished in
miR-520g expressing cells (Figure 6B and 6C), we did not
observe significant changes in transcriptional activity of a TCF/
LEF-driven reporter gene (pTOP-FLASH) in PFSK-miR-520g
cells (Figure S5). These collective observations suggest thatCdysregulation of WNT pathway genes observed in miR-520g
expressing stable cell lines and C19MC-amplified primary
tumors may reflect altered noncanonical WNT signaling.
Downstream effectors and targets of noncanonical WNT
signaling are poorly defined. It is known, however, that WNT5A
can associate with specific Frizzled receptors to induceancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Inc. 541
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Identifies CNS-PNET with Poor Survival and
Distinct Tumor Pathology
(A) Kaplan-Meier survival estimates for patients
stratified by C19MC amplification status in
tumors; log-rank analysis correlate C19MC ampli-
fication with poorer overall survival.
(B) Representative micrograph illustrating variant
and classic CNS-PNET histology and correspond-
ing frequency of C19MC amplication. Variant
histology distinguished by ependymal or ependy-
moblastic differentiation and distinct rosette
structures (arrows) correlate significantly with
C19MC amplication.
(C) Unsupervised hierarchical cluster analysis of
expression profiles for 33 CNS-PNET is shown in
relation to C19MC amplicon status and clinical
characteristics of tumor (Table S1). Red and white
boxes respectively denote presence or absence of
clinical features, and gray boxes denote incom-
plete information. Cluster analyses show cosegre-
gation (red cluster) and significant correlation of
tumors with C19MC amplification or increased
C19MC miRNA expression (Figure S7) with young
age (<4 years) and variant histology, but not with
tumor metastasis.
(D) Tabular summary indicating rarity of C19MC amplification in other pediatric brain tumors of different histologies. C19MC amplicon status was deter-
mined by FISH on tissue microarrays and/or SNP genotyping (CNS-PNET only).noncanonical WNT signaling and activate several downstream
effector kinases, including those of the Ca2+-dependent PKC
and CAMKII or the JNK pathways in various cell systems (Mikels
and Nusse, 2006; Miller, 2002). To investigate if upregulation of
WNT5A in CNS-PNET cells had any effect on noncanonical
WNT signaling, we performed western blot analysis of PFSK-
miR-520g cells using pan-PKC antibodies, which identify most
Ca2+-dependent phospho-PKC isoforms (PKC a, bI, bII), anti-
phospho-CAMKII, as well total and phospho-specific JNK1/2
antibodies. Interestingly, whereas phospho-PKC or CAMKII
levels were not altered with miR-520g expression, phospho-
JNK2, but not JNK1 levels were consistently upregulated in
PFSK cells with stable miR-520g expression as compared to
controls (Figure 6D shows representative of four independent
experiments), indicating that miR-520g maps upstream of
JNK2. In aggregate, our data correlate increased expression of
WNT5A and canonical WNT inhibitors, SFRP2 and DKK1, with
specific upregulation of phospho-JNK2 in PFSK-miR-520g cells,
and indicate a role for miR-520g in noncanonical WNT/JNK2
signaling. These findings are particularly intriguing, as recent
reports indicate canonical WNT activity may be linked to better
survival in CNS-PNET (Rogers et al., 2009) and suggest
C19MC amplification may portend poorer CNS-PNET pheno-
types.
Amplification of the C19MC Locus Defines
an Aggressive Group of CNS-PNET
To assess the significance of the C19MC locus in CNS-PNET
pathogenesis, we investigated if C19MC amplification corre-
lated with specific clinical features. Indeed, Kaplan Meier
analysis of 25 evaluable patients revealed substantially poorer
overall survival of patients with C19MC-amplified tumors
(mean survival 4 ± 1.3 months in amplified versus 44 ± 12.8
months in nonamplified cases; p < 0.0001) (Figure 7A). Interest-542 Cancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Incingly, theC19MC amplicon was also present at higher frequency
in tumors with variant histological features of ependymal or
ependymoblastic differentiation, (8/10 amplified versus 3/35
nonamplified tumors; p < 0.0005) and younger age at diagnosis
(10/11 amplified versus 14/25 nonamplified CNS-PNETs were
<4 yrs, p < 0.026) (Figures 7B and 7C). These collective data
suggested that the C19MC amplicon may identify a CNS-
PNET subgroup with distinct clinicopathological and genetic
features. Consistent with this hypothesis, we observed cosegre-
gation of C19MC amplified tumors in unsupervised cluster anal-
ysis of transcriptional profiles from 33 tumors (Figure 7C).
Remarkably, in a survey of 263 other pediatric brain tumors by
FISH analysis of tissue microarrays, we detected C19MC
amplicon in only one non-CNS-PNET tumor (an ependymoma)
(p < 0.00001) (Figure 7D). These data not only highlight the
importance of the oncogenic C19MC locus in CNS-PNET path-
ogenesis but suggest that the C19MC locus may represent a
specific marker for this tumor group.
DISCUSSION
In this study, we report the discovery of a large miRNA cluster on
chr19q13.41, C19MC, that is frequently amplified in aggressive
CNS-PNET and harbors miRNA oncogenes capable of driving
growth of normal hNSCs. We provide evidence that miR-520g
and 517c of the C19MC locus have oncogenic activity in vitro
and in vivo, confers cell survival, and promotes primitive/progen-
itor cell phenotypes by attenuating differentiation of hNSCs.
We correlate C19MC amplification in primary tumors and stable
miR-520g expression in hNSC and CNS-PNET cells with robust
dysregulation of WNT pathway loci and propose that C19MC
miRNA oncogenes confer aggressive tumor phenotype in part
by modulating WNT pathway signaling. Our findings have signif-
icant implications for clinical management of embryonal brain.
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genesis of CNS-PNET and oncogenic properties of the C19MC
locus.
Oncogenic Functions of the C19MC Locus
The functions of C19MC miRNAs are largely unknown;
however, many exhibit restricted expression in undifferenti-
ated/germinal tissues and cell types, such as placenta, testes
(Bentwich et al., 2005), and hESCs (Bar et al., 2008; Laurent
et al., 2008), indicating functions in cellular differentiation.
Indeed, Bar et al. (2008) observed that expression of miR-
520g, as well as four other C19MC miRNAs, diminishes with
hESC differentiation. Intriguingly, they also demonstrate that
C19MC may be regulated by NANOG and OCT4, known
critical transcriptional regulators of ESC pluripotentcy, and
propose that select C19MC miRNAs, including miR-520g,
may mediate self-renewal and represent ‘‘signatures’’ of
pluripotentcy in hESCs. In agreement with these studies, we
observed that miR-520g and 517c increases growth of hNSCs
under differentiation conditions. Importantly, our studies indi-
cate that miR-520g and 517c expression not only confer
increased cell survival but also promote stem/progenitor cell
phenotypes. Therefore, we propose that aberrant expression
of miR-520g and possibly other C19MC miRNAs alter normal
neuroepithelial stem/precursor response to cell differentiation
and survival stimuli and promote oncogenesis in part by
enhancing target stem/progenitor cell pools available for addi-
tional transforming events. Notably, although both miR-520g
and 517c cells confer cell survival in Daoy and PFSK tumor
cells, we observed more limited effects of miR-520g and
517c on growth and differentiation phenotypes of these tumor
cell lines (Figure S6), indicating that miR-520g and 517c
may also manifest cell-stage and type restricted cellular
effects/functions. Future in vivo experiments will be necessary
to directly assess the individual and collective effects of
miR-520g, 517c, as well other candidate C19MC miRNAs
oncogenes, on survival and self-renewal properties of neural
stem/progenitors cells.
A Role for miR-520g in WNT Signaling
We show that C19MC amplification and miR-520g expression
strongly correlate with altered WNT signaling in primary tumors
and stable tumor/hNSC cell lines, respectively. These findings,
which concur with computational analyses of miR-520g (Gaidat-
zis et al., 2007), are particularly interesting as substantial
evidence indicates aberrant WNT signaling may mediate malig-
nant transformation by promoting stem/progenitor cell expan-
sion in various developmental context, including the nervous
system (Kalani et al., 2008; Reya and Clevers, 2005). Interest-
ingly, WNT5A-mediated inhibition of canonical WNT signaling
has been shown to enhance hematopoietic stem/progenitor
cell repopulation (Nemeth et al., 2007). We observed decreased
CCND1 andMYCC expression in hNSCs and CNS-PNET cell line
PFSK with stable miR-520g expression; however, reporter gene
assays suggest that miR-520g does not significantly alter canon-
ical WNT signaling in PFSK cells. Although the canonical WNT
pathway has been most often highlighted in brain tumor devel-
opment, our collective studies suggest that WNT5A-associated
noncanonical WNT/JNK2 signaling, which is known to regulateCcell polarity and neuronal maturation (Ciani and Salinas, 2005),
is upregulated by miR-520g expression in hNSC and PFSK cells.
The role of noncanonical WNT signaling in neural stem cells
remains to be completely elucidated; however, our observations
lead us to speculate that oncogenic miR-520g, and possibly
other related C19MC miRNA, promotes transformation of neural
stem/progenitor cell pools by subverting WNT signaling.
While our aggregate data links miR-520g with altered WNT
signaling, the mechanism(s) by which miR-520g mediates this
effect remains to be determined. An analysis of miR-520 g-asso-
ciated gene sets in PFSK and hNSCs revealed few genes that
represented strong direct miR-520g targets, based on criteria
of target site prediction by at least 2 of 3 target prediction
programs and modest to strong conservation of target sites
(Watanabe et al., 2007). However, a comparative analysis of
2460 miR-520g target genes predicted by three algorithms
(Table S9) reveal a common set of 63 candidate genes, a subset
of which (TLE4,PRICKLE 2,BMP6,CAMK2N1,CUL3, LHX8, and
MAPRE1/EB1), represent promising candidates, as they are
implicated in WNT signaling and also exhibit one or more
conserved miR-520g binding sites. Our studies to date reveal
only limited gene expression changes of most candidate targets
in miR-520g expressing stable hNSC and PFSK cell lines; there-
fore, high-throughput reporter gene assays and proteomic anal-
ysis are underway to validate these predicted miR-520g targets.
It is important to point out that the three algorithms used for
identification of candidate miR-520g targets in our study rely
largely on sequence conservation. Although use of evolutionary
conservation has represented a key methodological advance for
target gene identification of highly conserved miRNAs, the
importance of such parameters for defining targets of poorly
conserved, primate-specific miRNAs, such as those of the
C19MC locus, remain unknown (Bartel, 2009). Significantly,
functionally validated targets without matched seed pairing
have been reported for a number of miRNAs including LIN28
(Wu and Belasco, 2005) and miR-24 (Lal et al., 2009). Targeting
of ‘‘seedless’’ 30UTR may represent a particularly important
mechanism for C19MC miRNAs, as they are characterized by
poorly defined seed sequence; thus, conventional seed-
matched algorithms as used in this study may only identify a
small subset of biologically relevant miR-520g targets.
Notably, many predicted miR-520g target genes also contain
binding sites for other candidate C19MC miRNA oncogenes,
including miR-517c and miR-519a. As recent studies indicate
that most miRNAs individually only have modest, modulatory
effects on gene transcription or translation (Baek et al., 2008;
Selbach et al., 2008), it is likely that miR-520g will require coop-
erativity with other noncoding or coding loci to effect robust
changes in gene regulation and cell signaling. In this regard, it
is interesting to note that in our study, we observed frequent
gains of chr2 in tumors with C19MC amplification; thus, in
addition to other C19MC miRNAs, which are overexpressed in
CNS-PNET, we speculate that one or more loci on chr2 may
also encode oncogenic partners of miR-520g.
Clinical Implications
Current treatment of malignant pediatric brain tumors with
chemo-radiotherapy engenders significant long-term neurocog-
nitive sequelae; therefore, there is substantial interest in applyingancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Inc. 543
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applications in tumor diagnosis, our data suggest the C19MC
locus may also have a prognostic role. A recent report described
the C19MC amplicon in a case of an embryonal brain tumor
characterized by ependymoblastic differentiation and proposed
association of C19MC with a specific nosologic entity (Pfister
et al., 2009). However, our studies indicate a significant, but
not exclusive, correlation of C19MC amplification with histology,
pointing to a broader role for the C19MC locus in CNS-PNET
pathogenesis. Specifically, a proportion of tumors that segre-
gate with the C19MC-amplified tumors lack characteristic
histology or C19MC amplification but exhibit increased expres-
sion of select C19MC miRNA oncogenes (Figure S7) and/or
chr2 gains. Future investigations of alternative mechanisms of
C19MC activation and/or other cooperating oncogenic loci
suggested by our studies will be an important step toward delin-
eating the scope ofC19MC functions and how they contribute to
the molecular pathogenesis of CNS-PNET.
Although the effects of treatment-related parameters could not
be fully evaluated inour patientcohort, the collective data from this
study provides a compelling basis for investigating the C19MC
locus as a biomarker in larger, homogenously treated cohorts of
CNS-PNET. As our experimental data link WNT pathway dysregu-
lation with oncogenic functions of theC19MCmiRNAs, it will also
be of interest to determine whether tumor phenotypes correlate
with specific patterns of WNT pathway activity.
We have identified recurrent amplification leading to overex-
pression of the C19MC locus in a human cancer and demon-
strate that at least 2 members of the cluster mediate oncogenic
effects. Our data links the C19MC amplicon to a distinctly
aggressive clinical phenotype and point to promising diagnostic
and therapeutic applications of this locus for pediatric embryonal
brain tumors. Together with recent reports that implicateC19MC
miRNAs in aggressive primary breast cancer (Foekens et al.,
2008), our findings suggest activation of the C19MC locus may
generally define aggressive human tumors. Combined with
recent success in blood-based detection (Mitchell et al., 2008)
and in vivo targeting of oncogenic miRNAs (Krutzfeldt et al.,
2005), our findings raise exciting possibilities to exploit C19MC
as a diagnostic tool and therapeutic target for a broader
spectrum of human cancers.
EXPERIMENTAL PROCEDURES
Tumor and Nucleic Acid Samples
Tumor samples and clinical information were collected with consent as per
protocols approved by the Hospital Research Ethics Board at participating
institutions (listed in Supplemental Data). Clinicopathological data is listed in
Table S1. Only tumors classified as CNS-PNET according to 2007 WHO
CNS tumor classification criteria (McLendon et al., 2007) were included.
DNA and RNA were extracted by standard methods; tumor histology was
reviewed by CH or CE. Pediatric brain tumor tissue microarrays were
previously described (Liang et al., 2008; Ray et al., 2004; Tabori et al., 2006).
Microarray and Fluorescence In Situ Hybridization Analysis
DNA and RNA array hybridizations were carried out by The Centre of Applied
Genomics Facility (TCAG), Hospital for Sick Children, Toronto (http://www.
tcag.ca/), using the Affymetrix 500K/250K NspI and 250 StyI GeneChip
Mapping arrays and the Illumina Human-6 V2 BeadChip array (http://www.
illumina.com), respectively. Hybridization methods, data collection, and
analysis are detailed in Supplemental Data. Dual-colored fluorescence544 Cancer Cell 16, 533–546, December 8, 2009 ª2009 Elsevier Incin situ hybridization (FISH) analyses were performed using prelabeled BAC
probes as detailed in Supplemental Data.
Immunoblot Assays and Quantitative Real-Time PCR Analysis
for DNA and mRNA
See Supplemental Data available online.
MicroRNA Expression Analysis with TaqMan MicroRNA Arrays
and qRT-PCR
See Supplemental Data available online.
Stable microRNA expression
To generate miR 517c and 520g expression plasmids, synthetic oligonucleo-
tides (Integrated DNA Technologies) containing mature miR-517c or miR-520g
and 25–40 bp of flanking precursor miRNAs sequences (Accession MI0003166
and M10003174, respectively, from http://microrna.sanger.ac.uk/sequences)
were cloned into a pcDNA3 vector (Invitrogen). Plasmid sequences are avail-
able upon request. Stable cell lines were generated by transfecting Daoy, NIH
3T3, and PFSK cells with pcDNA-miR-520g, miR-517c, or empty vector cells
selected in G418 (2.5 mg/ml) were tested for miRNA expression by qRT-PCR.
Cell Line Propagation, Growth, Survival, and Transformation Assays
See Supplemental Data available online.
Nude Mice Xenograft Assays
Protocols for animal experimentation were approved by the Hospital for Sick
Children Animal Care Committee and are described in Supplemental Data.
Human Neural Stem Cell Line Propagation, Growth,
and Differentiation Assays
An adherent human neural stem (hNSC) cell line was generated from a 50-day-
old fetal cortex with consent obtained under a Hospital for Sick Children
Research Ethics Board approved protocol and characterized according to
published methods (Sun et al., 2008). The hNSC line was propagated in
RHB-A media (Stem Cell Sciences Ltd.) with recombinant murine EGF and
human FGF-2 (10 ng/ml final concentration; Peprotech). Stable hNSC lines
were generated by nucleofection (Amaxa Biosystems) with pcDNA-miR-
520g and 517c plasmids and selection in G418-containing media for 14
days. For growth assays, stable hNSCs-miR-520g and 517c cell lines were
plated in 96-well dishes at 1000 cells/well, allowed to attach overnight under
proliferative conditions, and then switched to DMEM +10% FBS and moni-
tored for growth using an InCyte imaging system (Essen Instruments) or
MTT assay as described in Supplemental Data. Expression of differentiation
markers in stable miR-520 and 517c expressing hNSCs was determined using
FACS analysis with anti-Tubulin b-III (TuJ1 antibodies, 1:500, Chemicon), anti-
GFAP (1:300, monoclonal GA-5, Sigma monoclonal), and Alexa 405 or 488
anti-species antibodies (Invitrogen) as described previously (Pollard et al.,
2009).
Statistical Analyses
ANOVA method was used for time-series cell growth and survival experiments.
Significance of soft agar assays and correlation of gene expression with
chr19q13.41 amplification was determined using unpaired, two-tailed
Student’s t tests; p values were adjusted for multiple testing by FDR method
for comparison of tumor or cell line gene-expression profiles. A Wilcoxon
rank sum test was used to determine significance of xenograft studies. Corre-
lation of amplicon to survival was assessed using the Kaplan Meier method
and log-rank test (a = 0.05) and to age and histology by a two-sided Fisher’s
exact test.
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Microarray data from this study are available at NCBI Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession numbers
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